drugset / Trial / NCT00883155

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions

NCT00883155

Phase 1 Completed 36 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets under Fasting Conditions.

Timeline

Start
1998-10
Primary completion
1998-10
Completion
1998-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 100 mg

Indications

No indication recorded.